{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:58:22Z","timestamp":1785484702803,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2025.100559","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:56:54Z","timestamp":1766131014000},"page":"100559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Meta-analysis of clinical efficacy and safety of decitabine combined with CAG regimen in the treatment of acute myeloid leukemia in the elderly"],"prefix":"10.1016","volume":"25","author":[{"given":"Yanxia","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3318-5769","authenticated-orcid":false,"given":"Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2025.100559_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-020-00160-8","article-title":"Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis","volume":"9","author":"Wen","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.lrr.2025.100559_bib0002","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/bloodadvances.2020003195","article-title":"Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial","volume":"5","author":"Simoes","year":"2021","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.lrr.2025.100559_bib0003","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100559_bib0004","article-title":"Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications","volume":"96","author":"D'Angelo","year":"2020","journal-title":"Leuk Res."},{"issue":"11","key":"10.1016\/j.lrr.2025.100559_bib0005","doi-asserted-by":"crossref","first-page":"e1663","DOI":"10.1634\/theoncologist.2020-0818","article-title":"Cladribine with granulocyte colony-stimulating factor, cytarabine, and aclarubicin regimen in refractory\/relapsed acute myeloid leukemia: a phase II multicenter study","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.lrr.2025.100559_bib0006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Maiti","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.lrr.2025.100559_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-020-00160-8","article-title":"Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis","volume":"9","author":"Wen","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.lrr.2025.100559_bib0008","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.lrr.2025.100559_bib0009","first-page":"150","article-title":"Analysis of the application of CAG regimen combined with decitabine in the treatment for forty eladerly patients with acute myeloid leukemia","volume":"23","author":"Liu","year":"2017","journal-title":"J. Chin. Oncol."},{"issue":"5","key":"10.1016\/j.lrr.2025.100559_bib0010","first-page":"840","article-title":"Clinical efficacy and safety of decitabine combined with CAG regimen in elderly patients with acute myeloid leukemia","volume":"34","author":"Song","year":"2019","journal-title":"Pract. J. Cancer"},{"issue":"A01","key":"10.1016\/j.lrr.2025.100559_bib0011","first-page":"397","article-title":"Clinical effect analysis of DAC and CAG and CAG chemotherapy in the treatment of elderly patients with acute myeloid leukemia","volume":"38","author":"Xiong","year":"2018","journal-title":"J. Hunan Univ. Chin. Med."},{"issue":"5","key":"10.1016\/j.lrr.2025.100559_bib0012","first-page":"90","article-title":"Clinical efficacy of decitabine combined with CAG in the treatment of senile acute myeloid leukemia","author":"Cai","year":"2016","journal-title":"Shandong Med. J."},{"issue":"7","key":"10.1016\/j.lrr.2025.100559_bib0013","first-page":"871","article-title":"Efficacy of decitabine combined with half amount CAG chemotherapy regimen in treating elderly acute myeloid leukemia","volume":"19","author":"He","year":"2019","journal-title":"J. Trop. Med."},{"issue":"10","key":"10.1016\/j.lrr.2025.100559_bib0014","first-page":"62","article-title":"Efficacy and safety of decitabine in the treatment of senile acute myeloid leukemia","volume":"45","author":"Wang","year":"2017","journal-title":"Chin. J. Clin."},{"issue":"5","key":"10.1016\/j.lrr.2025.100559_bib0015","first-page":"613","article-title":"Observation on efficacy of decitabine combined with CAG regimen in treatment of the elderly with acute myeloid leukemia","volume":"18","author":"Gu","year":"2018","journal-title":"Eval. Anal. Drug-Use Hosp. China"},{"issue":"9","key":"10.1016\/j.lrr.2025.100559_bib0016","first-page":"697","article-title":"Analysis on clinical efficacy of decitabine combined with CAG regimen in elderly patients with acute myeloid leukemia","volume":"30","author":"Lu","year":"2017","journal-title":"J. Clin. Hematol."},{"issue":"14","key":"10.1016\/j.lrr.2025.100559_bib0017","first-page":"3500","article-title":"Effect of decitabine combined with CAG in the treatment of senile acute myeloid leukemia and its effect on immune function","volume":"37","author":"Chen","year":"2017","journal-title":"Chin. J. Gerontol."},{"issue":"10","key":"10.1016\/j.lrr.2025.100559_bib0018","first-page":"146","article-title":"Efficacy and prognosis of decitabine combined with CAG in the treatment of elderly patients with acute myeloid leukemia","volume":"40","author":"Sun","year":"2019","journal-title":"J. Med. Forum"},{"issue":"18","key":"10.1016\/j.lrr.2025.100559_bib0019","first-page":"3037","article-title":"Efficacy of decitabine combined with CAG in the treatment of senile acute myeloid leukemia","volume":"28","author":"Sun","year":"2017","journal-title":"Hainan Med. J."},{"issue":"12","key":"10.1016\/j.lrr.2025.100559_bib0020","first-page":"1469","article-title":"Effects of decitabine combined with CAG chemotherapy regimen on IGF-1,VEGF levels,and immune function of elderly patients with AML","volume":"45","author":"Lei","year":"2020","journal-title":"J. Guizhou Med. Univ."},{"issue":"9","key":"10.1016\/j.lrr.2025.100559_bib0021","first-page":"2109","article-title":"Effects of decitabine combined with low-dose CAG regimen on serum VEGF, TSGF, TGF-\u03b21, immune function and survival prognosis in elderly patients with AML","volume":"42","author":"Deng","year":"2022","journal-title":"Chin. J. Gerontol."},{"issue":"1","key":"10.1016\/j.lrr.2025.100559_bib0022","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1038\/s41467-020-18618-y","article-title":"A cell-type deconvolution meta-analysis of whole blood EWAS reveals lineage-specific smoking-associated DNA methylation changes","volume":"11","author":"You","year":"2020","journal-title":"Nat Commun."},{"issue":"7","key":"10.1016\/j.lrr.2025.100559_bib0023","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-21-3729","article-title":"Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed\/refractory acute myeloid leukemia","volume":"28","author":"Baer","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lrr.2025.100559_bib0024","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41408-022-00715-4","article-title":"The antileukemic activity of decitabine upon PML\/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation","volume":"12","author":"Meier","year":"2022","journal-title":"Blood Cancer J."},{"issue":"21","key":"10.1016\/j.lrr.2025.100559_bib0025","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lrr.2025.100559_bib0026","first-page":"1319","article-title":"Effects of combination of decitabine and CAG on cellular immunity, humoral immune indexes and adverse reactions in elderly patients with AML","volume":"48","author":"Lei","year":"2019","journal-title":"Chongqing Med."},{"issue":"5","key":"10.1016\/j.lrr.2025.100559_bib0027","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3892\/mco.2015.605","article-title":"Palliative chemotherapy followed by methylation inhibitor in high-risk acute myeloid leukemia: an in vitro and clinical study","volume":"3","author":"Ding","year":"2015","journal-title":"Mol Clin Oncol."},{"issue":"2","key":"10.1016\/j.lrr.2025.100559_bib0028","first-page":"515","article-title":"[Comparation of clinical efficacy between two regimens of preexcitation chemotherapy for MDS-RAEB patients]","volume":"27","author":"Pan","year":"2019","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:11:30Z","timestamp":1785481890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"alternative-id":["S2213048925000615"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100559","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis of clinical efficacy and safety of decitabine combined with CAG regimen in the treatment of acute myeloid leukemia in the elderly","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100559"}}